Nachrichten und Videos - NEOVACS - Englisch

Increase in the funding commitment of Néovacs to cover cash requirements through the topline results of the pivotal Phase III clinical study of the drug candidate PXT3003, the PREMIER trial, in development in Charcot-Marie-Tooth Disease Type1A (CMT1A) Appointment of Hugo Brugière as Chairman and CEO Creation of an ad hoc committee dedicated to the search for a strategic industrial partner to develop the Company's assets and potential PARIS, FRANCE / ACCESSWIRE / December 28, 2022 / Pharnext SA...

Paris and Boston, May 19 th , 2020 5:30 PM CET - Néovacs (Euronext Growth Paris: ALNEV) confirms that it has requested the resumption of trading in its shares on Euronext as soon as possible in accordance with the commitment made in its press release dated May 18 th , 2020 [1] . The resumption of trading follows on from the Paris Commercial Court's approval of the draft continuity plan presented by HBR Investment Group. The approval of the plan will enable Néovacs to close ongoing receivership...

End of court-ordered receivership proceedings Continuation of core research in lupus and allergies Creation of a new business investing in BioTechs and MedTechs New shareholder (HBR Investment Group) and changes in governance Restructuring of liabilities Transfer of ORNANE financing agreement of a total residual nominal amount of €5.85 million over a maximum period of 10 months, in favor of HBR Investment Group, and signing of a new OCEANE-BSA financing agreement for a maximum nominal amount...

Paris and Boston, May 4 th , 2020 – 18.00 CET - Néovacs (Euronext Growth Paris: ALNEV) today provides an update on the ongoing insolvency proceedings. The Paris Commercial Court will review the sole Néovacs draft continuity plan presented and submitted by HBR Investment Group, during a video-conference hearing scheduled for May 6 th , 2020 at 2.00 pm. The continuity plan primarily includes: Acquisition of an equity interest in Néovacs by HBR Investment Group as part of the continuity plan;...

Paris and Boston, March 9 th , 2020 – 6h30 pm CET - Neovacs (Euronext Growth Paris: ALNEV) announces that it has obtained a 6-month extension of its observation period and reports an update on the two research programs. REOGANIZATION PROCEEDINGS On November 26th, 2019 the Commercial Court of Paris decided the opening of reorganization proceedings of the company with an observation period initially set for 3 months. At the end of this period and after a hearing before the Tribunal held in the...

COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE OPENING OF A CALL FOR TENDER TO PROVIDE A CONTINUATION OR SALE PLAN IN THE FRAME OF REOGANIZATION PROCEEDINGS The deadline for submission of all tenders is January 10 th , 2020 before 04:00pm Paris and Boston, December 6 th , 2019 – 05h45pm CET - Neovacs (Euronext Growth Paris : ALNEV) announces the launch of a call for tender opened from now until January 10 th , 2020 before 4:00 pm, to provide a continuation plan through...

PRESS RELEASE PRESS RELEASE · PRESS RELEASE · PRESS RELEASE PRESS RELEASE NEOVACS ANNOUNCES ITS 2019 HALF-YEAR RESULTS Paris and Boston, 2 nd October, 2019— 9:30 p.m. CEST—NEOVACS (Euronext Paris: ALNEV, eligible for PEA-PME), a leading provider of therapeutic vaccines for the treatment of autoimmune diseases, announced today its 2019 half-year results for the period ending on 30 th June 2019, approved by the Board of Directors on 2 nd October 2019. Results for the first half of 2019: Cash...

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS ANNOUNCES APPOINTMENT OF VINCENT SERRA AS CHIEF EXECUTIVE OFFICER Paris & Boston, September 30, 2019 – 08h30am CEST - Neovacs (Euronext Growth Paris: ALNEV), a leader in active immunotherapies for the treatment of auto-immune diseases, has today announced, the appointment of Vincent Serra, PhD, as the new Chief Executive Officer, with immediate effect, to succeed Miguel Sieler who has resigned as CEO and as a board director. Jean-Jacques...

PRESS RELEASE PRESS RELEASE PRESS RELEASE 2019 Financial Calendar Paris, September 9, 2019, 5:45 pm CEST – NEOVACS (Euronext Growth Paris: ALNEV) leader in active immunotherapy for the treatment of auto-immune and inflammatory diseases publishes an updated 2019 financial calendar today. Financial announcements will be published before the market opening. The expected dates are preliminary so may be subject to change. 2019 First Half Results October 2, 2019 2019 Annual Results March 29, 2020...

· PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS ANNOUNCES THAT THE POSITIVE RESULTS OF ITS PROOF OF CONCEPT IN ALLERGIES WITH IL-4 / IL-13 KINOID HAVE TRIGGERED THE FIRST PAYMENT OF THE ANR GRANT Paris and Boston, July 9, 2019 – Neovacs – 7:30 am CEST - (Euronext Growth Paris : ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, has today announced having received a first payment within the grant awarded by the National Agency for Research (ANR)...

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS ANNOUNCES THE APPOINTMENT of Dr. VIRGINIA PASCUAL AS MEDICAL AND SCIENTIFIC ADVISOR Paris and Boston, June 27 th , 2019 – Neovacs – 7:30 am CEST - (Euronext Growth Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announces the appointment of Dr. Virginia Pascual as Medical and Scientific advisor . “ We are delighted to welcome Dr Pascual to Neovacs. Her significant contribution to lupus...

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS TO PRESENT THE PRE-CLINICAL RESULTS OF ITS IFNα KINOID TO TREAT TYPE 1 DIABETES AT T HE AMERICAN DIABETES ASSOCIATION'S 79TH SCIENTIFIC SESSIONS (ADA) “IFNα Kinoid: A promising vaccine against Type 1 Diabetes Targeting IFN-alpha in NOD Mice” San Francisco, CA, USA - June 7- 11, 2019 Paris and Boston, June 5, 2019 – Neovacs – 7:30 am CEST - (Euronext Growth Paris : ALNEV), a leader in active immunotherapies for the treatment of...

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS TO PRESENT THE PRE-CLINICAL RESULTS OF ITS THERAPEUTIC VACCINE CANDIDATE IL-4 / IL-13 KINOID TO TREAT ALLERGIC ASTHMA « Antibodies and Complement 2019 » - Girona, Spain- May 20-25, 2019 « EAACI 2019 » - Lisbon, Portugal, June 1-5 2019 Paris and Boston, May 16, 2019 – Neovacs - 07h30 am CEST - (Euronext Growth Paris : ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced the presentation...

RESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS REPORTS FULL-YEAR 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE KEY OPINION LEADERS VALIDATE THE THERAPEUTIC POTENTIAL OF IFNα KINOID IN LUPUS TREATMENT FOLLOWING THE RESULTS OF THE PHASE IIB CLINICAL STUDY SUCCESSFUL IN VIVO PROOF OF CONCEPT FOR ITS IL-4 / IL-13 KINOID A NEW THERAPEUTIC VACCINE TO TREAT MITE-INDUCED ASTHMA PATENT REGISTERED IN EUROPE AND THE U.S. FOR IL-4 / IL-13 KINOID, CANDIDATE VACCINE IN THE TREATMENT OF...

COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE AGENDA FINANCIER 2019 Paris et Boston, le 19 février 2019 – NÉOVACS (Euronext Growth Paris : ALNEV), leader de l’immunothérapie active pour le traitement des maladies auto-immunes, présente aujourd’hui son agenda financier 2019. Les publications financières auront lieu avant ouverture du marché. Ce calendrier est indicatif et peut être soumis à modifications. Résultats annuels 2018 mardi 16 avril 2019 Assemblée...

NEOVACS TO HOST KOL MEETING TO DISCUSS ITS THERAPEUTIC VACCINE IFN α KINOID FOR LUPUS TREATMENT FEBRUARY 11, 2019 – 17h00 Hôtel Renaissance Le Parc Trocadéro – Paris Paris and Boston, February 5 th 2019 – 7h30 CET - Neovacs (Euronext Growth Paris: ALNEV), leader in active immunotherapy for the treatment of auto-immune and inflammatory diseases announces an event with Key Opinion Leaders specializing in auto-immune diseases and rheumatology to discuss its ground breaking product, the...

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS TO PRESENT FULL RESULTS FROM THE PHASE IIb IFNalpha KINOID CLINICAL STUDY AT THE 13 TH INTERNATIONAL LUPUS CONGRESS (LUPUS 2019) 5 - 9 APRIL, SAN FRANCISCO Paris & Boston, January 24 th , 2019 – 17:45 pm CET - Neovacs (Euronext Growth Paris: ALNEV), leader in active immunotherapy for the treatment of auto-immune and inflammatory diseases announces that it has been selected to present the results of its Phase IIb IFNα Kinoid clinical...

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS SECURES FINANCING FROM THE ANR - THE FRENCH NATIONAL RESEARCH AGENCY - TO DEVELOP THE IL-4/IL-13 KINOID AS AN ALLERGY TREATMENT Paris and Boston, January 8, 2019 - 7:30 CET - Neovacs (Euronext Paris Growth Paris: ALNEV), leader in active immunotherapy for the treatment of auto-immune diseases, announces that its AllergyVACS project has been selected to receive funding from the French National Research Agency (ANR) following the latter's...

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE Neovacs and Centurion Pharma continue their collaboration in Lupus based on the results of the Phase IIb trial with IFNalpha Kinoid Paris and Boston, December 11 th 2018 - 7:30 am CET - Neovacs (Euronext Growth Paris: ALNEV ), leader in the field of active immune therapy for the treatment of autoimmune-diseases, confirms the decision of Centurion Pharma to pursue the partnership on the basis of the licensing agreement signed between both companies...

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE Neovacs announces the patent filing in Europe and in the United States for its new therapeutic vaccine candidate Kinoid IL-4/IL-13 for the treatment of allergies Paris and Boston, November 20 th 2018 - 17h45 CET (Euronext Growth Paris: ALNEV), leader in active immunotherapy for the treatment of autoimmune and inflammatory diseases, announces patent filing after having achieved preclinical proof of concept with its new vaccine IL-4/IL-13 Kinoid for...